
ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL
Two Onc Docs
00:00
Safety profile of pirtobrutinib
Kareen reviews key toxicities: bleeding, arthralgias, hypertension, and low atrial fibrillation rates.
Play episode from 06:43
Transcript


